Lyophilized vs. reconstituted: which actually needs cold chain?

We sell cold chain packaging. Publishing a page that says one common product form does not obviously need it is not a comfortable position, and we have thought about whether to write it. We are writing it because the alternative is joining the large body of vendor content that answers this question by asserting the conclusion that sells the most refrigerant, and because a pharmacy that over-specifies packaging on the wrong SKU has less budget for the SKU that genuinely needs it.

Why lyophilization changes the chemistry

Freeze-drying removes the water. That single fact shuts down most of the pathways by which a peptide degrades — hydrolysis and deamidation both require water as a participant, and microbial growth requires it as a medium. What remains in a well-sealed lyophilized vial are slow processes driven by residual moisture, oxygen that works its way past an imperfect closure, and trace catalytic impurities left from processing. These operate on a timescale of months, not the hours a parcel spends in a delivery vehicle.

The clearest published measurement of this for a peptide compounding pharmacies actually handle comes from a 2026 solid-state stability study of semaglutide in Pharmaceutical Research:

The shape of that curve is what matters. Between baseline and 60°C the loss is modest and gradual. Between 60°C and 80°C the structure falls apart entirely. There is a cliff, and it sits well above any temperature a payload inside an insulated container reaches in transit — even granting reported summer vehicle interiors as high as 121°F, which is an air temperature that a vialed solid does not equilibrate to during a transit window.

Why solution-state is a different problem

Reconstitute the same peptide and every pathway lyophilization closed reopens at once. Hydrolysis, deamidation, and oxidation resume; sterility becomes a live concern; and aggregation becomes possible in a way it simply is not in the solid state.

Published work on semaglutide in solution establishes two things worth carrying into a packaging decision. First, pH is the dominant driver of thermal degradation — not temperature acting alone. Formulation buffer and molarity substantially change how the same thermal exposure plays out, which is why borrowing another product’s excursion allowance for your preparation is not sound. Second, semaglutide in aqueous solution forms oligomeric micelles and a population of needle-shaped fibrils, with dimers and trimers appearing at lower concentrations.

That aggregation finding is where the safety argument stops being about potency. The FDA’s own advisory committee briefing material on peptide compounding states the concern directly:

Peptides “can be extremely sensitive to product formulation, process, and environmental conditions (e.g., pH, heat, temperature, concentration, in-process related impurities, excipients),” and the agency “cannot rule out the potential for immunogenicity associated with these impurities and peptide-related aggregates.”

FDA, Pharmacy Compounding Advisory Committee briefing document

A degraded peptide is not simply a weaker one. Aggregates are the recognised mechanism by which a protein therapeutic provokes an immune response. That is the argument for cold chain on reconstituted product, and it is considerably stronger than “it might not work as well.”

What this means for a packaging decision

Two consequences follow that are easy to miss.

The humidity question deserves more attention than it gets. If the real vulnerability of a lyophilized product is water rather than heat, then closure integrity, desiccant, and barrier performance matter more than refrigerant mass — and a packout optimised purely for thermal hold may be solving the wrong problem. This is close to unexamined in vendor literature, ours included until now.

Most product that ships to patients is not lyophilized powder. The compounded preparations moving through 503A and 503B pharmacies to patients are overwhelmingly solutions in vials or pens. The thermal robustness of the dry form is genuinely interesting and largely academic for the shipping decision most pharmacies are actually making.

So does Meridian recommend less packaging?

For genuinely lyophilized product on a short lane, sometimes yes — and we would rather say so than sell a 72-hour packout to protect something that does not need protecting. Where we think the money belongs is on reconstituted and finished sterile preparations, where the chemistry is unambiguous, and on the freeze side of the problem, which most pharmacies underestimate.

We would also rather you find this out from your own data than from ours. Request a lane test and we will run a sample packout on your actual route with the chamber data alongside it.